诺华任命新CEO！年仅41岁！“我想为全世界研发新药！”

诺华是世界上药物研发支出最大的公司之一，几个月后将由一位药物开发专家领导。

2017年9月4日，星期一上午，诺华公司宣布，现任CEO Joe Jimenez先生将在2018年2月份离任，将把诺华公司的管理大权交付给年仅四十一岁的Vas Narasimhan医学博士。Narasimhan博士2005年加入诺华，现任诺华全球药物开发总管兼首席医学官，是尖端科学的热心倡导者，一直以来在公司一系列成功的项目中表现突出，他领导的这些项目为诺华带来了下一波重磅炸弹。

Vasant Narasimhan at a January 2017 news conference in Basel michele limina/bloomberg

Narasimhan现在加入了生物制药行业中最高级最独特的俱乐部，生物制药公司首席执行官俱乐部，其活动遍及全球。任命Narasimhan博士为下一任首席执行官，总部位于瑞士巴塞尔的诺华公司继续聘用美国人当最高统帅。不同之处在于，Narasimhan博士并像大部分CEO同行那样拥有营销或法律背景，他致力于新药开发，带来的是新产品开发方面的丰富经验。

Narasimhan博士的任命在世界上第一个CAR-T疗法Kymriah（tisagenlecleucel）的历史性获批之后迅即来到。Kymriah被广泛认为是具有深远治疗潜力的重大科学突破。

这位年轻的开发主管也在其它药物上取得了成功，包括：治疗心脏病的抗炎药物卡那霉素（canakinumab）、与安进合作开发的新一代偏头痛后期药物、治疗复发多发性硬化症的BAF312（siponimod）、一系列的生物仿制药，以及诸如牛皮癣药物Consentyx等药物的附加数据。

研发的征程中充满挫折（例如，serelaxin），但Narasimhan博士在过去的18个月里成功领导了全球行业里最大的研发管线之一，仅去年的研发费用就高达90亿美元。

2018年2月1日走马上任的Narasimhan博士将与董事会紧密合作，该董事会以永不停止地追求成本效率而闻名。诺华公司在过去几年中接连失去了多位顶尖人才，但也引进了新一代的科学家，如Dana-Farber的Jay Bradner医学博士。

现在问题来了，Narasimhan博士统领三军后将如何改变研发呢？ 过去一年里，制药行业里的每一位新任CEO，诸如GSK、礼来、Biogen及其它公司，新官上任三把火的第一把都是首先重组公司的研发管线并开始新一轮的交易。Jimenez先生曾躲避行业并购，行将上任的Narasimhan博士如何在当今甚至中型规模的交易都没有吸引力的市场中驾驶诺华这支航空母舰继续乘风破浪向前航行呢？

Narasimhan博士承诺，该公司将继续其全球范围的努力以获得具有变革意义的疗法的关键数据，这些疗法可以为患者带来重大影响，同时为公司赚取数十亿美元的收入。

Narasimhan博士表示：

我们将继续发扬我们为世界各地的患者带来领先的创新产品的传统。我们最新产品的上市、强大的研发管线、广泛的创新能力、世界一流的领导团队和兢兢业业全身心投入的同事，这一切令我对我们的未来充满信心。

2016年1月份，时任诺华制药全球研发负责人的Vas Narasimhan博士尚在非洲工作。他在一部短片中与大家分享了如何从祖母身上学到谦逊的精神、最看重的人品特质以及为何喜欢阅读与工作不相关的书籍。

...........................

https://v.qq.com/txp/iframe/player.html?vid=r0177tjgfnl&width=500&height=375&auto=0

—— 欢迎欣赏诺华公司的新闻稿！ ——

Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.

SEP 04, 2017

Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The Board of Directors has appointed Vasant (Vas) Narasimhan, M.D., Global Head of Drug Development and Chief Medical Officer, as CEO of Novartis, effective February 1, 2018. Dr. Narasimhan is a member of the Executive Committee and joined Novartis in 2005.

Mr. Jimenez, who has been CEO since 2010, joined the company in 2007. He first led the Consumer Health Division, and then held the position of Division Head, Novartis Pharmaceuticals. Mr. Jimenez will step down as CEO, effective January 31, 2018, and will be available for advice and support at the request of the Chairman of the Board of Directors or the CEO until he retires from Novartis on August 31, 2018.

Joerg Reinhardt, Chairman of the Novartis Board of Directors, commented, "I would like to express my sincere appreciation for Joe's achievements as CEO. During his tenure, Joe focused Novartis on leading global businesses, while divesting non-core divisions. Under his leadership the innovation pipeline was rejuvenated, and we successfully navigated the patent expirations of our two largest products. We anticipate a smooth transition as Joe built a strong leadership team and mentored his successor. Novartis will be well positioned to continue its momentum."

Mr. Jimenez said, "Both from a professional and a personal perspective, this is the right moment to hand the leadership reins of the company to Vas. Our strong pipeline and the strategic moves we have taken to focus the company have put Novartis on a strong path for the future. On the personal side, after 10 wonderful years in Switzerland, my family is ready to return to Silicon Valley and the US. I'm confident that Vas will be an excellent successor."

Dr. Narasimhan has held numerous leadership positions across Novartis in commercial, drug development and strategy roles. Prior to his current role he served as Head of Development for Novartis Pharmaceuticals. Before joining Novartis in 2005, he worked at McKinsey & Company. He received his medical degree from Harvard Medical School in the US and obtained a master's degree in public policy from Harvard's John F. Kennedy School of Government. In addition, he holds a bachelor's degree in biological sciences from the University of Chicago, also in the US. During and after his medical studies, he worked extensively on a range of health issues in developing countries. Dr. Narasimhan is an elected member of the US National Academy of Medicine. He is a US citizen born in 1976, married with 2 children, and lives in Basel, Switzerland.

Mr. Reinhardt added, "The strength of Novartis is our ability to drive science-based innovation. Vas is deeply anchored in medical science, has significant experience in managing the interfaces between Research and Development and commercial units and has strong business acumen with a track record of outstanding achievements. As a physician, he has a strong patient focus and a genuine humane perspective and care for the mission and values of Novartis. As a result, the Board of Directors is confident that Vas is the right choice to lead Novartis on our expected next growth phase, driving innovation and further strengthening our competitive position."

Dr. Narasimhan said, "I would like to congratulate Joe and express my gratitude to Joe, Joerg, and the Board of Directors. I feel honored and humbled to be asked to lead Novartis. We will continue our legacy of bringing leading innovation to patients around the world. With our recent launches, our strong pipeline, broad capabilities, world-class leadership team, and committed people, I am very confident about our future."

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "to retire," "effective," "will," "pipeline," "anticipate," "well positioned," strategic," "future," "confident," "next growth phase," "driving," "strengthening," "launches," "committed," or similar expressions, or by express or implied discussions regarding potential potential future sales or earnings of the Novartis Group. You should not place undue reliance on these statements. Such forward looking statements are based on our the current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward looking statements. There can be no guarantee that Novartis will be commercially successful in the future, or achieve any particular financial results. In particular, our expectations could be affected by, among other things: regulatory actions or delays or government regulation generally; the potential that the strategic benefits, synergies or opportunities expected from the significant reorganizations of recent years may not be realized or may take longer to realize than expected; the uncertainties inherent in the research and development of new healthcare products; our ability to obtain or maintain proprietary intellectual property protection on key products; safety, quality or manufacturing issues; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; uncertainties regarding actual or potential legal proceedings; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

For a portrait of Dr. Narasimhan, please visit https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis(link is external)
For Novartis multimedia content, please visit www.novartis.com/news/media-library

For questions about the site or required registration, please contact [e-mail]

备注：药时代本着推荐、分享有价值的信息的宗旨，进行编译。因水平有限，不当、错误之处难免，我们对译文的质量负全部的责任，热烈欢迎朋友、老师们的批评指正！

参考资料及重要声明：

* Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO（作者：John Carroll，发表时间：2017年9月4日）；

* 见解 | 从医学院学生到全球研发负责人：“我想为全世界研发新药”（来源：诺华集团，发表时间：2016年1月27日）

图片来源：原文、诺华官网、Google，等。

所有版权归拥有者！

药时代编译，旨在分享有价值的信息，仅供个人学习参考。欢迎阅读原文，对译文批评指正！衷心感谢！

—— 欢迎阅读近3个月内10,000+文章！——

欢迎联系我们！[e-mail]